We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for General Dynamics, DuPont, & Merck
Read MoreHide Full Article
Wednesday, November 23 2016
Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD - Free Report) , DuPont (DD - Free Report) and Merck (MRK - Free Report) .
Buy rated General Dynamics’s shares have gained nearly 24% this year. The analyst likes its recent contract wins, such as the $125.6 million contract to offer program management and system support for Rescue 21, the U.S. Coast Guard's advanced communications system. Going ahead, General Dynamics expects to see solid growth momentum post 2017, following the introduction of the G500 in 2018, major revenue recognition from Combat Systems’ huge backlog and the Ohio-class Replacement (ORP) submarine program. (You can read the full research report on General Dynamics here.)
DuPont’s shares have increased 6.5% this year. The analyst likes Buy rated DuPont’s aggressive cost-cutting actions and new product launches. The company continues to impress operationally, with Q3 results coming in better than expected, outlook for the current period raised and management reassuring about the Dow deal. DuPont has unveiled redesign actions to support its more focused portfolio of businesses following the spinoff of the performance chemicals unit. Moreover, it remains committed to maximize shareholder value. (You can read the full research report on DuPont here.)
Merck shares have gained more than 17% year-to-date on the back of strong momentum in its product pipeline. The company's better than expected Q3 results and positive guidance are adding to the momentum as well. The analyst likes Merck’s new products, especially Keytruda, which should continue to contribute meaningfully to the top line. The latest FDA approval of Keytruda for the first line treatment of metastatic lung cancer should sharply improve the drug’s sales. Merck has also made significant progress with its pipeline and is working on bringing new products to the market. However, generic competition and pricing pressure will continue to pressurize the top line. (You can read the full research report on Merck here.)
Today's Private Buys & Sells from Zacks Research While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for General Dynamics, DuPont, & Merck
Wednesday, November 23 2016
Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD - Free Report) , DuPont (DD - Free Report) and Merck (MRK - Free Report) .
Buy rated General Dynamics’s shares have gained nearly 24% this year. The analyst likes its recent contract wins, such as the $125.6 million contract to offer program management and system support for Rescue 21, the U.S. Coast Guard's advanced communications system. Going ahead, General Dynamics expects to see solid growth momentum post 2017, following the introduction of the G500 in 2018, major revenue recognition from Combat Systems’ huge backlog and the Ohio-class Replacement (ORP) submarine program. (You can read the full research report on General Dynamics here.)
DuPont’s shares have increased 6.5% this year. The analyst likes Buy rated DuPont’s aggressive cost-cutting actions and new product launches. The company continues to impress operationally, with Q3 results coming in better than expected, outlook for the current period raised and management reassuring about the Dow deal. DuPont has unveiled redesign actions to support its more focused portfolio of businesses following the spinoff of the performance chemicals unit. Moreover, it remains committed to maximize shareholder value. (You can read the full research report on DuPont here.)
Merck shares have gained more than 17% year-to-date on the back of strong momentum in its product pipeline. The company's better than expected Q3 results and positive guidance are adding to the momentum as well. The analyst likes Merck’s new products, especially Keytruda, which should continue to contribute meaningfully to the top line. The latest FDA approval of Keytruda for the first line treatment of metastatic lung cancer should sharply improve the drug’s sales. Merck has also made significant progress with its pipeline and is working on bringing new products to the market. However, generic competition and pricing pressure will continue to pressurize the top line. (You can read the full research report on Merck here.)
Other noteworthy reports we are featuring today include Oracle (ORCL - Free Report) , Marriott (MAR - Free Report) and Blackstone (BX - Free Report) .
Today's Private Buys & Sells from Zacks Research
While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>